Category: Cardiovascular - page 4

CANTOS Trial (2017): Canakinumab for Atherosclerotic Disease

2017, CANTOS Trial: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, NEJM The CANTOS trial evaluated the inflammatory nature of coronary artery disease where hypothesis was that decreasing the inflammation marker such as interleukin 1B will result in lower incidence of cardiovascular events. For this purpose, canakinumab which is a monoclonal antibody against IL-1B was tested..

Read more

FOURIER Trial (2017): Evolocumab and Clinical Outcomes in Patients with CVD

FOURIER Trial Key Points: FOURIER trial established the role of PCSK9 inihibitor therapy in reducing future cardiovascular events and mortality. Evolocumab showed benefit in terms of cardiovascular disease but didn’t show any mortality benefit. These agents were utilized in patients who were already on moderate to high intensity statin therapy. PCSK9 inhibition was well-tolerated without excess new-onset diabetes..

Read more

FRISC II Trial (2006): Invasive vs non-invasive treatment in unstable CAD

1999, Invasive compared with non-invasive treatment in unstable coronary-artery disease, The Lancet The FRISC II trial established the role of early intervention in patients with UA/NSTEMI. The study compared maximal medical therapy or non invasive approach with intervention and showed significant decrease in the incidence of MI. The combine MI and/or mortality was found to..

Read more

TIMACS Trial (2009): Early versus Delayed Invasive Intervention in ACS

2009, TIMACS trial: Early vs delayed invasive intervention in acute coronary syndrome, NEJM TIMACS trial addressed the question of when to intervene in patients who come to hospital with unstable angina and/or NSTEMI. Although the results showed no benefits of early intervention but in subgroup analysis, the results were significantly in favor of performing early..

Read more

RESPECT Trial (2013): Closure of PFO versus Medical Therapy after Cryptogenic Stroke

2013, Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke, NEJM RESPECT Trial Key Points: Patients with cryptogenic stroke have higher incidence of PFO compared to general population. This led to the concept that closing PFO might be beneficial in terms of preventing recurrence of stroke in this population. The initial CLOSURE I trial showed no..

Read more